LENZ Therapeutics (LENZ) Liabilities and Shareholders Equity (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $272.5 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 35.42% year-over-year to $272.5 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 19.36% increase from a year earlier, with the FY2025 full-year figure at $305.9 million, up 42.07% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $272.5 million, down from $305.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for LENZ reached as high as $378.6 million in Q1 2022 and fell as low as $70.4 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $258.2 million across 5 years, with a median of $266.2 million in 2023.
• Across the five-year window, Liabilities and Shareholders Equity sank 78.14% in 2023 and surged 205.93% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $321.9 million in 2022, then sank by 78.14% to $70.4 million in 2023, then jumped by 205.93% to $215.3 million in 2024, then surged by 42.07% to $305.9 million in 2025, then slipped by 10.9% to $272.5 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $272.5 million in Q1 2026, $305.9 million in Q4 2025, and $210.7 million in Q3 2025.